LifeStance Health Group (NASDAQ:LFST) CTO Sells $541,402.29 in Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) CTO Vukasin Paunovich sold 42,067 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $12.87, for a total value of $541,402.29. Following the completion of the sale, the chief technology officer directly owned 205,379 shares of the company’s stock, valued at $2,643,227.73. This trade represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Vukasin Paunovich also recently made the following trade(s):

• On Monday, August 10th, Vukasin Paunovich sold 44,394 shares of LifeStance Health Group stock. The shares were sold at an average price of $10.85, for a total transaction of $481,674.90.

LifeStance Health Group Trading Down 0.8%

Shares of NASDAQ LFST traded down $0.10 during mid-day trading on Friday, reaching $12.73. 2,043,233 shares of the company’s stock were exchanged, compared to its average volume of 3,445,051. LifeStance Health Group, Inc. has a 52-week low of $4.77 and a 52-week high of $13.15. The firm has a market capitalization of $4.94 billion, a price-to-earnings ratio of 97.93 and a beta of 1.22. The company’s 50-day moving average is $11.44 and its 200-day moving average is $8.77. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The business had revenue of $435.35 million for the quarter, compared to the consensus estimate of $414.58 million. During the same period in the previous year, the firm earned ($0.01) EPS. The business’s revenue was up 26.1% on a year-over-year basis. Analysts expect that LifeStance Health Group, Inc. will post 0.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Larson Financial Group LLC increased its holdings in shares of LifeStance Health Group by 19,952.6% in the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock valued at $27,000 after acquiring an additional 3,791 shares during the period. KBC Group NV purchased a new position in LifeStance Health Group during the first quarter worth about $29,000. EverSource Wealth Advisors LLC lifted its position in LifeStance Health Group by 359.1% in the first quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock valued at $44,000 after purchasing an additional 5,404 shares during the period. PNC Financial Services Group Inc. boosted its holdings in LifeStance Health Group by 615.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock valued at $59,000 after purchasing an additional 7,987 shares in the last quarter. Finally, Assetmark Inc. boosted its holdings in LifeStance Health Group by 17.0% in the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock valued at $60,000 after purchasing an additional 1,367 shares in the last quarter. Hedge funds and other institutional investors own 85.50% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on LFST. BTIG Research boosted their target price on LifeStance Health Group from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, August 19th. The Goldman Sachs Group started coverage on LifeStance Health Group in a research note on Friday, June 5th. They issued a “neutral” rating and a $9.00 price objective for the company. KeyCorp boosted their price objective on LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Wall Street Zen upgraded shares of LifeStance Health Group from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings upgraded shares of LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $12.38.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.